GlassScriptPhysician profile
Amjad Shidyak
NPI 1902061054
$7,327.52
in general payments reported to CMS, 2019-2025
48 companies · $1,620 in 2025
The $1,620 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,545 · 2020: $290 · 2021: $245 · 2022: $991 · 2023: $1,334 · 2024: $1,302 · 2025: $1,620.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,256.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,255.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,221.29 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,159.80 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $447.29 | 2022-2025 | Vraylar, Qulipta, Ubrelvy |
| Dexcom, INC. | $364.41 | 2021-2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $358.27 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $317.22 | 2019-2025 | |
| Lilly USA, LLC | $291.43 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boston Scientific Corporation | $283.33 | 2025 | General - Pain Management |
| Boehringer Ingelheim Pharmaceuticals, INC. | $282.91 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $251.69 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Sanofi-Aventis U.S. LLC | $244.76 | 2019-2023 | |
| Amgen INC. | $243.55 | 2019-2025 | Repatha, Otezla, Evenity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $204.04 | 2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $142.62 | 2022-2025 | Rexulti |
| Medtronic, INC. | $137.00 | 2022 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amjad Shidyak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.